A study to evaulate the effects of antihypercholesterolemic agent, rosuvastain/ezetimibe on immune T-cell in type 2 diabetic patients with hypercholesterolemia
- Conditions
- Endocrine, nutritional and metabolic diseases
- Registration Number
- KCT0003477
- Lead Sponsor
- Chungnam National University Hospital
- Brief Summary
The fractions of CD8+CD57+ (senescent CD8+ T cells) and CD4+FoxP3 +(Treg) signi?cantly decreased after intervention in the rosuvastatin/ezetimibe group (-4.5 ± 14.1% and -1.2 ± 2.3%, respectively), while these fractions showed minimal change in the rosuvastatin group (2.8 ± 9.4% and 1.4 ± 1.5%, respectively). The degree of LDL-C reduction was correlated with an improvement in HbA1c (R=0.193, p=0.021). Changes in the CD8+CD57+ fraction positively correlated with patient age (R=0.538, p=0.026). Notably, the fraction change in senescent CD8+ T cells showed no signi?cant relationship with changes in either HbA1c (p=0.314) or LDL-C (p=0.592). Finally, the ratio of naïve to memory CD8+ T cells increased in the rosuvastatin/ezetimibe group (p=0.011), but not in the rosuvastatin group (p=0.339).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 56
1. patients with type 2 diabetes mellitus
2. serum LDC-C level is 100 mg/dL or more
1. currently lipid lowering therapy
2. AST/ALT level - more 2.5X than normal
3. CK level - more 3X than normal
4. allergy or side effect to study drug or statin
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method expression rate of senescence CD8+ T-cell
- Secondary Outcome Measures
Name Time Method serum level of LDL-cholesterol